Sunshine Act Meeting: Board of Scientific Counselors NCEH/ATSDR; Cancelation, 32188 [2017-14745]
Download as PDF
<![CDATA[
32188
Federal Register / Vol. 82, No. 132 / Wednesday, July 12, 2017 / Notices
increasing the probability that
customers would pay higher prices for
fibre channel switches and that
innovation would be lessened.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Entry
Entry into the worldwide fibre
channel switch market is not likely to
occur in a timely, likely, or sufficient
magnitude, character and scope to deter
or counteract any anticompetitive
effects created by the proposed
Acquisition. Entry is unlikely in light of
slowly declining demand for fibre
channel switches in a mature market,
customers that tend to stay with one
fibre channel switch manufacturer for
extended periods of time, and the
significant capital costs required for
entry.
The Consent Agreement
To remedy the alleged competitive
concern stemming from Broadcom’s
access to Cisco’s competitively sensitive
confidential information, the consent
decree prevents the Cisco information
from being shared among Broadcom
employees who could use such
information to raise prices or lessen
innovation.
Pursuant to the proposed Order, only
authorized individuals will have access
to Cisco’s competitively sensitive
confidential information that is given to
the firewalled entity, which is defined
as Broadcom’s business group
responsible for the development,
production, sale, and marketing of fibre
channel ASICs for Cisco. The firewalled
entity will have separate facilities and a
separate information technology system
with security protocols assuring access
only to the authorized individuals.
Furthermore, Broadcom shall require all
authorized individuals to sign a nondisclosure agreement, requiring
compliance with the terms of the
proposed Order. Additionally, the
proposed Order provides for a cooling
off period whereby any authorized
individual who leaves his or her
position at the firewalled entity will not
work in the development, production,
sale, or marketing of fibre channel
ASICs for Brocade’s business unit or in
the development, production, sales, and
marketing of fibre channel switches for
twelve months.
The proposed Order also requires
Broadcom to use Cisco’s competitively
sensitive confidential information only
in furtherance of the design,
manufacturing, and sale of fibre channel
ASICs for Cisco. Moreover, Broadcom
will be required to take all actions
necessary to prevent access to, or the
disclosure or use of Cisco’s
competitively sensitive confidential
VerDate Sep<11>2014
17:54 Jul 11, 2017
Jkt 241001
information by or to anyone who is not
an authorized individual. The proposed
Order also incorporates by reference
non-disclosure provisions contained in
four prior private Confidentiality
Agreements that Broadcom, or its
predecessor, signed with Cisco.
To ensure compliance with the
proposed Order, the Commission will
appoint a Monitor to oversee
Broadcom’s and Brocade’s performance
of their obligations pursuant to the
Consent Agreement. The Monitor will
be appointed to a five-year term, but the
Commission may extend or modify the
term as appropriate up to a ten-year
period. Further, the Consent Agreement
contains appropriate reporting
requirements.
Opportunity for Public Comment
The purpose of this analysis is to
facilitate public comment on the
proposed Consent Agreement to aid the
Commission in determining whether it
should make the proposed Consent
Agreement final. This analysis is not an
official interpretation of the proposed
Consent Agreement and does not
modify its terms in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2017–14536 Filed 7–11–17; 8:45 am]
BILLING CODE 6750–01–P
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2017–14745 Filed 7–10–17; 4:15 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0002]
New Animal Drugs; Withdrawal of
Approval of a New Animal Drug
Application
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of withdrawal.
The Food and Drug
Administration (FDA) is withdrawing
approval of two new animal drug
applications (NADAs). This action is
being taken at the sponsor’s request
because these products are no longer
manufactured or marketed.
SUMMARY:
Withdrawal of approval is
effective July 24, 2017.
DATES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Sunshine Act Meeting: Board of
Scientific Counselors NCEH/ATSDR;
Cancelation
FEDERAL REGISTER CITATION OF PREVIOUS
ANNOUNCEMENT: The original Federal
Register Notice for this meeting was
published in the Federal Register on
May 22, 2017, Volume 82, Number
2017–10333, page/s/23250–23251.
PREVIOUSLY ANNOUNCED TIME AND DATE OF
THE MEETING: 9:00 a.m.–noon, EDT, June
23, 2017.
This meeting is
being canceled in its entirety.
CONTACT PERSON FOR MORE INFORMATION:
Amanda Malasky, BS, ORISE Fellow,
CDC, 4770 Buford Hwy., Atlanta, GA
30344, telephone 770–488–7699; yoo0@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
CHANGES IN THE MEETING:
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Sujaya Dessai, Center for Veterinary
Medicine (HFV–212), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–402–5761,
sujaya.dessai@fda.hhs.gov.
Zoetis,
Inc., 333 Portage St., Kalamazoo, MI
49007 has requested that FDA withdraw
approval of NADA 065–291 for bulk
dihydrostreptomycin sulfate and NADA
065–324 for bulk streptomycin sulfate
because the products are no longer
manufactured or marketed.
Therefore, under authority delegated
to the Commissioner of Food and Drugs,
and in accordance with § 514.116 Notice
of withdrawal of approval of application
(21 CFR 514.116), notice is given that
approval of NADA 065–291 and NADA
065–324, and all supplements and
amendments thereto, is hereby
withdrawn, effective July 24, 2017.
As neither of these NADAs was
codified, the animal drug regulations do
not require amendment to reflect the
voluntary withdrawal of approval of
these applications.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\12JYN1.SGM
12JYN1
]]>Agencies
[Federal Register Volume 82, Number 132 (Wednesday, July 12, 2017)]
[Notices]
[Page 32188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14745]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Sunshine Act Meeting: Board of Scientific Counselors NCEH/ATSDR;
Cancelation
FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: The original
Federal Register Notice for this meeting was published in the Federal
Register on May 22, 2017, Volume 82, Number 2017-10333, page/s/23250-
23251.
PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 9:00 a.m.-noon, EDT,
June 23, 2017.
CHANGES IN THE MEETING: This meeting is being canceled in its entirety.
CONTACT PERSON FOR MORE INFORMATION: Amanda Malasky, BS, ORISE Fellow,
CDC, 4770 Buford Hwy., Atlanta, GA 30344, telephone 770-488-7699;
yoo0@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2017-14745 Filed 7-10-17; 4:15 pm]
BILLING CODE 4163-18-P
